Topics

Ovid Therapeutics Announces Participation in Two Upcoming Investor Conferences

20:00 EDT 2 Sep 2019 | Globe Newswire

NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced its participation in two upcoming investor conferences in September:

  • Citi’s 14th Annual Biotech Conference
    Members of the Company’s management team will participate in one-on-one meetings with investors on Thursday, September 5, 2019. The conference will be held at the Four Seasons Hotel in Boston, MA.
  • Ladenburg Thalmann’s 2019 Healthcare Conference
    Jeremy Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer of Ovid, will present a corporate overview on Tuesday, September 24, 2019 at 9:00 a.m. EDT.  Ovid will also participate in one-on-one meetings with investors. The conference will be held at the Sofitel Hotel in New York, NY.

A live audio webcast of the presentation at the Ladenburg conference can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the company's website for two weeks following the live presentation.

About Ovid Therapeutics
Ovid Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).

For more information on Ovid, please visit http://www.ovidrx.com/.

Contacts

Investors and Media:
Ovid Therapeutics Inc.
Investor Relations & Public Relations
irpr@ovidrx.com

Or

Investors:
Steve Klass
Burns McClellan, Inc.
sklass@burnsmc.com
(212) 213-0006

Media:
Katie Engleman
1AB
katie@1abmedia.com
(919) 333-7722

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Ovid Therapeutics Announces Participation in Two Upcoming Investor Conferences"

Quick Search

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...